Company: STAA
Filing Date: 2025-09-16
Form Type: DEFM14A
Source: 0001193125-25-204396
Chunk: 83

Company: STAAR SURGICAL CO
Filing Date: 2025-09-16
Form: DEFM14A
Chunk 83
---
 Agreement.                                                              |

| • |     | Stockholder Appraisal Rights. The Board also considered the availability of appraisal rights under 
 Delaware law to any holders of shares of STAAR common stock who do not vote in favor of the        |

-50-

| adoption of the Merger Agreement and who comply with all of the required statutory procedures, which provides those eligible stockholders with an opportunity to have a Delaware court determine 
 the fair value of their shares, which may be more than, less than or the same as the amount such stockholders would have received under the Merger Agreement.                                    |

| • |     | Opinion of Citigroup Global Markets Inc. The Board considered the oral opinion rendered by Citi to the                                                                                                                                                   
 Board, which was confirmed by delivery of a written opinion, dated August 4, 2025, to the effect that, as of such date and based upon and subject to the factors and assumptions set forth in its written opinion, the Merger Consideration of           
 $28.00 in cash per share of STAAR common stock to be received by the STAAR stockholders pursuant to the Merger Agreement was fair, from a financial point of view, to such holders. For more information, see the section of this proxy statement titled 
 “—Opinion of STAAR’s Financial Advisor” (the full text of the written opinion of Citi, dated August 4, 2025, which sets forth, among other things, the assumptions made, procedures followed, matters considered and                                     
 limitations on the review undertaken in connection with Citi’s opinion, is attached as Annex B to this proxy statement and is incorporated herein by reference).                                                                                         |

| • |     | Potential Benefits to Patients and Surgeons. The Board considered that STAAR, as a subsidiary of Alcon                                                                                                                                            
 (and indirect subsidiary of Alcon Inc.), would have access to the advantages provided by Alcon Inc.’s size and operational experience, including with respect to additional access to capital and marketing, and the resulting ability to provide 
 STAAR’s products to a greater number of surgeons and patients.                                                                                                                                                                                    |

The Board also considered a variety of risks and other potentially negative factors in its consideration of the Merger Agreement and the Merger, including the following:

| • |     | the fact that consummation of the Merger depends on the satisfaction or waiver of certain conditions which are                                 
 outside of STAAR’s control, and the risk that one or more of such conditions could fail to be satisfied or waived on